Research Update

Phytopharm PLC
05 June 2007


Company Contact:                                U.K. Investor Relations Contact:
Phytopharm plc                                  FD
Dr Daryl Rees CEO                               David Yates
Mr Piers Morgan CFO                             Ben Atwell
[phone]                                [phone]
www.phytopharm.com


Cogane(TM) data presented at '11th International Congress of Parkinson's Disease
and Movement Disorders'

GODMANCHESTER, Cambridgeshire, U.K. (5 June 2007) - Phytopharm plc (LSE: PYM) 
('Phytopharm' or the 'Company') announces today pre-clinical data showing that
Cogane(TM) reverses the changes in the area of the brain involved in Parkinson's
disease.  This data will be presented by Dr Jonathan Brotchie, an
internationally recognised expert on Parkinson's disease at 'The 11th
International Congress of Parkinson's Disease and Movement Disorders' 5 June in
Istanbul, Turkey and published in The Movement Disorders Society's journal*.

Cogane(TM) reverses the changes in area of the brain involved in Parkinson's
disease by inducing the production of neurotrophic factors.  These growth
factors promote the growth and connectivity of neurones and reverse the atrophy
of this area of the brain.  This latest study was partly funded by The Cure
Parkinson's Trust.

Commenting, Tom Isaacs, co-founder of The Cure Parkinson's Trust said:  
'Cogane's ability to induce a person's own neurotrophic activity offers a very
real prospect of a better treatment for Parkinson's disease. As a patient led
organisation, The Cure Parkinson's Trust is very excited about the potential of
this product to completely restore motor function to those with the condition.
We are delighted our targeted fund allocation in this area of research has been
directly involved in these latest findings.'

Commenting, Dr Daryl Rees, Chief Executive Officer of Phytopharm, said: 'There
is an urgent need for new therapeutic approaches to Parkinson's disease.
Pre-clinical studies with Cogane(TM),  an orally bioavailable neurotrophic factor
inducer, have been highly encouraging  in reversing the changes in the area of
the brain involved in Parkinson's disease, providing hope that Cogane(TM) could
restore normal control of movement.'


                                     -Ends-

                                Notes to Editors

Phytopharm plc

Phytopharm is a pharmaceutical development and functional food company whose
product leads are generated from medicinal plants.  The Company's strategy is to
develop these products through 'proof of principle' clinical testing, and then
secure partners for late stage development, sales and marketing. Laboratory,
manufacturing and clinical work is outsourced to selected specialists, operating
under expert in-house management.  This operational structure allows access to
the best external research facilities whilst maintaining low fixed overheads and
a lower development cost structure.

Cogane(TM)

Cogane(TM) (PYM50028) is a novel non-peptide, orally bioavailable neurotrophic
factor inducer that readily crosses the blood brain barrier.  In pre-clinical
studies, Cogane(TM) stimulates the release of neuronal growth factors, increases
neurite outgrowth and protects against neuronal degeneration.  Importantly,
Cogane(TM) also reverses the decrease of neuronal growth factors and reverses
dopaminergic neuronal degeneration observed in vitro.  When administered orally
to pre-clinical models of Parkinson's disease, Cogane(TM) reverses the loss of
dopaminergic neurones.

  *Movement Disorders (2007) Vol 22 (Suppl 16): page S18, abstract number 58.

Parkinson's disease

Parkinson's disease is a movement disorder characterised by muscle rigidity,
tremor, a slowing of physical movement (bradykinesia) and, in extreme cases, a
loss of physical movement (akinesia). The primary symptoms are the result of
altered signaling of an area of the brain, the striatum, responsible for the
control of movement.  This is caused by degeneration of dopaminergic neurones
between the striatum and the substantia nigra part of the brain leading to
insufficient formation and action of dopamine.  Parkinson's disease is therefore
termed a neurodegenerative disease.  The disease is slow in onset and the
appearance of symptoms reflects the gradual loss of dopaminergic neurones.

The prevalence of the disease is estimated to be 100 to 200 per 100,000
population (Source: Datamonitor).  In the US alone, there are estimated to be
one million patients with diagnosed Parkinson's disease with associated
healthcare costs to the economy of $25 billion (Source: Northwest Parkinson's
Foundation submission to US Congress).  Parkinson's disease can affect people of
any age, though the incidence is higher in older people.  Individuals will
experience varying combinations of the symptoms, each with differing degrees of
severity.  The cause of Parkinson's disease in the majority of cases is unknown
(idiopathic Parkinson's disease), though some cases have been found to have a
hereditary component (familial Parkinson's disease) and possible mechanisms
include oxidative damage of nerve cells coupled with loss of neurotrophic
factors.  Neurotrophic factors are essential for the survival and maintenance of
nerve cells and provide protection against toxic insults, however as proteins,
their utility as pharmacological treatments are limited (Source: The Cure
Parkinson's Trust).

At present, there is no cure for Parkinson's disease, but a variety of
medications provide relief from the symptoms, usually by dopamine replacement
therapy either by L-DOPA, which is converted to dopamine in the striatum, or by
dopamine agonists which act on the dopamine receptors to restore normal motor
function (control of movement).  However, both treatments cause either less
endogenous dopamine to be released or the dopamine receptors to become
progressively less sensitive, thereby eventually increasing the symptoms.  There
is an urgent need for the development of new approaches to this debilitating
condition and non-peptide orally bioavailable neurotrophic factor inducers that
readily cross the blood brain barrier represent an important therapeutic
approach.

For further information about Phytopharm please see our website at 
http://www.phytopharm.com

Dr Jonathan Brotchie

Dr Jonathan Brotchie is Senior Scientist at the Toronto Western Hospital, part
of the University Health Network (UHN) in Toronto, Canada.  He is also the
Founder and Chief Executive Officer of Atuka Ltd., a contract research and
consultancy services company for the development of novel therapeutics and
diagnostics for Parkinson's disease.  Jonathan is a renowned scientist in the
field of Parkinson's disease and, at UHN runs one of the world's premier
research laboratories for the identification of novel treatments, diagnostics
and cures for Parkinson's and related disorders.  In the last decade, he has
published many influential scientific papers in the field of Parkinson's disease
and related disorders.  His research has been particularly associated with
pioneering the concept of non-dopaminergic treatments for Parkinson's disease.

Jonathan is also Scientific Director of the Cure Parkinson's Trust, a charity
supporting research aimed at delivering better treatments and cures for PD.

The Cure Parkinson's Trust

The Cure Parkinson's Trust supported by Movers & Shakers was co-founded by four
individuals with Parkinson's who are determined to do everything in their power
to help find a cure for this debilitating neurological disease.  They are former
Lord Mayor of London, Sir Richard Nichols, David Jones CBE, former chairman of
Next Plc, Michael Hughes and Tom Isaacs.

Parkinson's disease can affect anyone at any time. It does not discriminate by
age, sex or nationality.  One in every 500 people, contracts Parkinson's, with
one in every 20 of those diagnosed each year being under the age of 40 years.  A
cure for Parkinson's disease is within reach.

The Cure Parkinson's Trust has been funding a variety of research projects
globally.  For further details see: www.cureparkinsons.org.uk


                      This information is provided by RNS
            The company news service from the London Stock Exchange